Literature DB >> 9246062

99mTc-HMPAO granulocyte scintigraphy in the early detection of postoperative asymptomatic recurrence in Crohn's disease.

L Biancone1, F Scopinaro, M Ierardi, P Paoluzi, A Marcheggiano, M C Di Paolo, B Porowska, A C Colella, F Pallone.   

Abstract

The usefulness of 99mTc-HMPAO scintigraphy in the early detection of postoperative recurrence of Crohn's disease was evaluated in 17 patients undergoing ileocecal resection and prospectively followed up for one year. Scintigraphy was performed 6 and 12 months after surgery and recurrence assessed by colonoscopy within two weeks. As controls, four patients with ileocecal resection for cecal carcinoma were studied. To perform scintigraphy, autologous granulocytes were labeled with 99mTc-HMPAO, injected, and tau-camera images acquired after 30 min and 3 hr. Six months after surgery, 4/8 Crohn's disease patients showed endoscopic recurrence, and 30-min scintigraphy was positive only in these four patients (four true positives, four true negatives). At 12 months, endoscopic recurrence was detected in 10/14 Crohn's disease patients, and 30-min scintigraphy was positive in 9/14 patients (eight true positives, three true negatives, two false negatives, one false positive). Scintigraphy at 3 hr showed a lower specificity in detecting CD recurrence both at 6 and 12 months. The endoscopic and 30-min scintigraphic score were significantly correlated both at 6 and 12 months (P = 0.007; P = 0.04). Scintigraphy was negative in 4/4 controls at 30 min (four true negatives) and positive in 1/4 (one false positive) at 3 hr. We conclude that 99mTc-HMPAO scintigraphy at 30 min is a sensitive technique for the early detection of Crohn's disease recurrence in patients under regular follow-up after surgery.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9246062     DOI: 10.1023/a:1018843516651

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  21 in total

1.  Reoperation and recurrence in Crohn's colitis and ileocolitis Crude and cumulative rates.

Authors:  A J Greenstein; D B Sachar; B S Pasternack; H D Janowitz
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Crohn's disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis.

Authors:  H E LOCKHART-MUMMERY; B C MORSON
Journal:  Gut       Date:  1960-06       Impact factor: 23.059

3.  Technetium-99m hexamethyl propylene amine oxine leucocytes in the assessment of disease activity in inflammatory bowel disease.

Authors:  E Lantto; K Järvi; I Krekelä; T Lantto; M Taavitsainen; H Vedenkangas; M Vorne
Journal:  Eur J Nucl Med       Date:  1992

4.  Inflammation: imaging with Tc-99m HMPAO-labeled leukocytes.

Authors:  M E Roddie; A M Peters; H J Danpure; S Osman; B L Henderson; J P Lavender; M J Carroll; R D Neirinckx; J D Kelly
Journal:  Radiology       Date:  1988-03       Impact factor: 11.105

5.  Ulcerative colitis serum recognizes the M(r) 40K protein on colonic adenocarcinoma cells for antibody-dependent cellular cytotoxicity.

Authors:  L Biancone; K M Das; A I Roberts; E C Ebert
Journal:  Digestion       Date:  1993       Impact factor: 3.216

6.  Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease.

Authors:  C Prantera; F Pallone; G Brunetti; M Cottone; M Miglioli
Journal:  Gastroenterology       Date:  1992-08       Impact factor: 22.682

7.  Scintigraphic assessment of bowel involvement and disease activity in Crohn's disease using technetium 99m-hexamethyl propylene amine oxine as leukocyte label.

Authors:  J Schölmerich; E Schmidt; C Schümichen; P Billmann; H Schmidt; W Gerok
Journal:  Gastroenterology       Date:  1988-11       Impact factor: 22.682

8.  Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group.

Authors:  C Brignola; M Cottone; A Pera; S Ardizzone; M L Scribano; R De Franchis; A D'Arienzo; G D'Albasio; D Pennestri
Journal:  Gastroenterology       Date:  1995-02       Impact factor: 22.682

9.  Technetium-99m hexamethyl propylene amine oxime granulocyte scintigraphy in Crohn's disease: diagnostic and clinical relevance.

Authors:  G Sciarretta; A Furno; M Mazzoni; C Basile; P Malaguti
Journal:  Gut       Date:  1993-10       Impact factor: 23.059

10.  Usefulness of fecal alpha 1-antitrypsin clearance and fecal concentration as early indicator of postoperative asymptomatic recurrence in Crohn's disease.

Authors:  M Boirivant; F Pallone; A Ciaco; M Leoni; S Fais; A Torsoli
Journal:  Dig Dis Sci       Date:  1991-03       Impact factor: 3.199

View more
  6 in total

Review 1.  Role of scintigraphy in inflammatory bowel disease.

Authors:  Maria I Stathaki; Sophia I Koukouraki; Nikolaos S Karkavitsas; Ioannis E Koutroubakis
Journal:  World J Gastroenterol       Date:  2009-06-14       Impact factor: 5.742

Review 2.  Diagnostic imaging and radiation exposure in inflammatory bowel disease.

Authors:  Nekisa Zakeri; Richard C G Pollok
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

Review 3.  Technetium leukocyte imaging in inflammatory bowel disease.

Authors:  M Charron
Journal:  Curr Gastroenterol Rep       Date:  1999-06

Review 4.  Postoperative Crohn's disease recurrence: a practical approach.

Authors:  Pilar Nos; Eugeni Domenech
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

5.  99mTc-interleukin-2 and (99m)Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease.

Authors:  Alessio Annovazzi; Livia Biancone; Renato Caviglia; Marco Chianelli; Gabriela Capriotti; Stephen J Mather; Renzo Caprilli; Francesco Pallone; Francesco Scopinaro; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-09       Impact factor: 9.236

Review 6.  Grading of Crohn's disease activity using CT, MRI, US and scintigraphy: a meta-analysis.

Authors:  C A J Puylaert; J A W Tielbeek; S Bipat; J Stoker
Journal:  Eur Radiol       Date:  2015-06-17       Impact factor: 5.315

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.